期刊文献+

HPLC-荧光法测定人血浆中替米沙坦血药浓度的方法改进 被引量:3

Improvement of HPLC-Fluorometric Method in the Determination of Telmisartan in Human Plasma
原文传递
导出
摘要 目的:改进以高效液相色谱-荧光法测定人血浆中替米沙坦浓度的方法.方法:以萘普生为内标,采用乙酸乙酯提取的方法处理血浆.色谱柱为Symmetry C8,流动相为乙腈-0.01mol·L^-1磷酸二氢钾溶液(47:53),流速为1.0mL·min^-1荧光检测波长为305nm(激发波长)、365nm(发射波长),进样量为20μL.结果:替米沙坦检测浓度在2.5~200ng·mL^-1范围内线性关系良好(r=0.999 8).最低检测限为1ng·mL^-1.方法的提取回收率为(89.91±10.07)%,日内和日间RSD<10%.样品3次冻融及提取后在24h内稳定性良好.结论:本方法操作简便、灵敏度和精确度高、重现性好,适于替米沙坦的体内药物浓度测定和药动学研究. OBJECTIVE: To improve the HPLC-fluorometrie method in the determination of telmisartan in human plasma.METHODS: Using naproxen as internal standard, the plasma was extracted with ethyl acetate.The separation was performed on Symmetry Ca with mobile phase consisted of aeetonitrile -0.01tool · L^ -1 potassium dihydrogen phosphate buffer solution(47 : 53) at a flow rate of 1.0ml · min^ -1.The λEx was set at 305nm and the ),Era was set at 365nm, and the sample size was 20μL.RESULTS:The linear range of telmisartan was 2.5--200ng · mL^ -1( r = 0.999 8) ,with the lowest deteetable limit at 1ng · mL^ -1.The average reeovery of extraetion was (89.91 + 10.07) % .Both the intra - day RSD and inter - day RSD were less than 10% .The sample showed a good stability within 24 hours after three freeze- thaw cycles and extractions.CONCLUSI- ON:The method is simple, sensitive,accurate and reproducible,and suitable for the determination and pharmaeokinetie study of telmisartan in human plasma.
出处 《中国药房》 CAS CSCD 北大核心 2007年第20期1556-1558,共3页 China Pharmacy
关键词 替米沙坦 高效液相色谱-荧光法 血浆 药物浓度 Telmisartan HPLC - fluorometrie method Plasma Plasma drug level
  • 相关文献

参考文献6

二级参考文献33

  • 1张志华,丁劲松,郭欣,彭文兴.替米沙坦3种制剂人体相对生物利用度研究[J].中国药房,2005,16(6):447-449. 被引量:2
  • 2侯飞燕,黄平,谭志荣,李智.替米沙坦片的人体生物等效性研究[J].中国药房,2006,17(4):282-284. 被引量:4
  • 3Wienen W, Hauel N,Van meel JCA, et al. Pharmacological characterization of the novel nonpeptide angiotension Ⅱ receptor antagonist,BIBR-277[J]. Br J Pharmacol,1993,110:245-252.
  • 4Stangier J, Schmid J,Turk D, et al. Absorption,metabolish andexcret-Ion of int-ravenously and orally administered [ C14 ] telmisartan in healthy volunteers [J]. J Clin Pharmacol, 2000,40:1338-1346.
  • 5Mcclellan KJ, Markham A. Telmisartan[J]. Drugs, 1998,56(6):1039-1044.
  • 6Stangiet J,Su CA, Hendriks MGC, et al.The effect of telmisartan on the steady state pharmcokinetics of digoxin in healthy male volunteers[J]. J Clin Pharmacol ,2000,40(121) : 1373-1379.
  • 7Timmemans PBMWM, Wong PC, Chiu AT, et al. Angiotensin Ⅱreceptors and Angiotensin Ⅱ receptor antagonists [ J ] . Pharmacol Rev, 1993,45(2) :205.
  • 8Hillaert S, van den Bossche W. Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-Ⅱ-receptor antagonists[ J ]. J Chromatogr A, 2002, 979 ( 1-2) :323.
  • 9Hillaert S, van den Bossche W. Simultaneous determination of hydrochlorothiazide and several angiotensin-Ⅱ-receptor antagonists by capillary electrophoresis [ J ]. J Pharm Biomed Anal, 2003,31 (2):329.
  • 10Stangier J,Su CA, Brickl R, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20mg and 120mg in subjects with hepatic impairment compared with healthy volunteers [ J ]. J Clin Pharmacol ,2000, 40(12 Pt 1): 1355.

共引文献29

同被引文献30

  • 1魏飙,王一倩,周达新.替米沙坦与吲哒帕胺联合应用治疗轻、中度高血压的临床疗效[J].中国临床药学杂志,2004,13(5):267-269. 被引量:5
  • 2陈永玲,朱家壁,丁义华.HPLC法测定家兔血浆中厄贝沙坦的浓度[J].江苏药学与临床研究,2006,14(3):153-155. 被引量:4
  • 3Wienen W, Hauel N, Van Meel JC, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensinⅡ receptor antagonist, BIBR 277[J]. Br J Pharmacol, 1993, 110(1):245-252.
  • 4Wienen W, Entzeroth M, van Meel JCA, Stangier J, Busch U, Ebner T, et al. Review on telmisartan: a novel long-acting angiotensinⅡ receptor antagonist[J]. Cardiovasc Drug Rev, 2000, 18:127-156.
  • 5Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension[J]. Adv Ther, 1998, 15:206-217.
  • 6Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives[J]. Drug Saf, 2003, 26(10):707-720.
  • 7Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension[J]. Int J Clin Pract, 1999, 53(3):175-178.
  • 8Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension[J]. Adv Ther, 1998, 15:229-240.
  • 9Hernández-Hernández R, Velasco M, Armas-Hernández MJ, Armas-Padilla MC. AngiotensinⅡ receptor antagonists in arterial hypertension[J]. J Hum Hypertens, 2000, 14(Suppl 1):S69-S72.
  • 10Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release[J]. Fundam Clin Pharmacol, 2005, 19(6):637-645.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部